{"filing":{"accession_number":"0001193125-26-271055","cik":"0001434316","ticker":"FATE","company_name":"FATE THERAPEUTICS INC","form":"8-K","filing_date":"2026-06-15","report_date":null,"primary_document":"fate-20260612.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526271055/fate-20260612.htm"},"events":[{"id":10998,"run_id":9638,"accession_number":"0001193125-26-271055","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"FATE Therapeutics held its Annual Meeting of Stockholders on June 12, 2026, with stockholders approving four proposals: election of three Class I Directors, ratification of Ernst \u0026 Young LLP as auditor, non-binding advisory vote on named executive officer compensation, and approval of a third amendment and restatement of the 2022 Stock Option and Incentive Plan increasing available shares by 7,000,000.","company_name":"FATE THERAPEUTICS INC","ticker":"FATE","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7467,"accession_number":"0001193125-26-271055","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of a third amendment and restatement of the 2022 Stock Option and Incentive Plan, increasing available shares by 7,000,000. This is a material compensatory arrangement affecting the equity incentive pool available to directors and officers, directly impacting future compensation capacity and shareholder dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:06:11.699212+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7468,"accession_number":"0001193125-26-271055","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of FATE's Annual Meeting of Stockholders held on June 12, 2026. The filing presents voting outcomes for four proposals: election of three Class I Directors (all approved), ratification of Ernst \u0026 Young LLP as auditor (approved), non-binding advisory vote on named executive officer compensation (approved), and approval of a stock option plan amendment to increase shares reserved by 7,000,000 (approved). The detailed vote tallies (for, against, abstain, broker non-votes) for each matter are provided, which is the hallmark of shareholder vote result disclosures. This is material as it confirms stockholder approval of key governance and compensation matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:06:11.699212+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7467,"accession_number":"0001193125-26-271055","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of a third amendment and restatement of the 2022 Stock Option and Incentive Plan, increasing available shares by 7,000,000. This is a material compensatory arrangement affecting the equity incentive pool available to directors and officers, directly impacting future compensation capacity and shareholder dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:06:11.699212+00:00","company_name":"FATE THERAPEUTICS INC","ticker":"FATE","filing_date":"2026-06-15"},{"id":7468,"accession_number":"0001193125-26-271055","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of FATE's Annual Meeting of Stockholders held on June 12, 2026. The filing presents voting outcomes for four proposals: election of three Class I Directors (all approved), ratification of Ernst \u0026 Young LLP as auditor (approved), non-binding advisory vote on named executive officer compensation (approved), and approval of a stock option plan amendment to increase shares reserved by 7,000,000 (approved). The detailed vote tallies (for, against, abstain, broker non-votes) for each matter are provided, which is the hallmark of shareholder vote result disclosures. This is material as it confirms stockholder approval of key governance and compensation matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:06:11.699212+00:00","company_name":"FATE THERAPEUTICS INC","ticker":"FATE","filing_date":"2026-06-15"}]}